Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129


Molecular profiling in non-small cell lung cancer: a step toward personalized medicine.

Raparia K, Villa C, DeCamp MM, Patel JD, Mehta MP.

Arch Pathol Lab Med. 2013 Apr;137(4):481-91. doi: 10.5858/arpa.2012-0287-RA. Review.


Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA.

J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4. Review.


KRAS mutation: should we test for it, and does it matter?

Roberts PJ, Stinchcombe TE.

J Clin Oncol. 2013 Mar 10;31(8):1112-21. doi: 10.1200/JCO.2012.43.0454. Epub 2013 Feb 11. Review.


Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR.

J Clin Oncol. 2010 Feb 20;28(6):918-27. doi: 10.1200/JCO.2009.25.2890. Epub 2010 Jan 25.


Personalized medicine for non-small-cell lung cancer.

Mok TS, Zhou Q, Leung L, Loong HH.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1601-11. doi: 10.1586/era.10.76. Review.


Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A.

Br J Cancer. 2008 Sep 16;99(6):923-9. doi: 10.1038/sj.bjc.6604629.


Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.

Wu JY, Yang CH, Hsu YC, Yu CJ, Chang SH, Shih JY, Yang PC.

Clin Lung Cancer. 2010 Jul 1;11(4):257-63. doi: 10.3816/CLC.2010.n.033.


Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.

Riess JW, Wakelee HA.

Clin Adv Hematol Oncol. 2012 Apr;10(4):226-34.


EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.

Han HS, Eom DW, Kim JH, Kim KH, Shin HM, An JY, Lee KM, Choe KH, Lee KH, Kim ST, Koo JH, Lee HC, Lee OJ.

Clin Lung Cancer. 2011 Nov;12(6):380-6. doi: 10.1016/j.cllc.2011.02.006. Epub 2011 May 20.


[Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].

Zhou Q, Shi Y, Chen J, Liu B, Wang Y, Zhu D, Zhang HT, Xu P, Gong Y, Chen G, Wei S, Qiu X, Niu Z, Chen X, Lei Z, Duan L, Wu Z.

Zhongguo Fei Ai Za Zhi. 2011 Feb;14(2):86-106. doi: 10.3779/j.issn.1009-3419.2011.02.15. Chinese. Erratum in: Zhongguo Fei Ai Za Zhi. 2011 Jul 20;14(7):592.


Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.

Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N.

Tumori. 2007 Sep-Oct;93(5):473-7.


Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F.

J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3. Erratum in: J Clin Oncol. 2011 Dec 10;29(35):4725.


EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

de Mello RA, Madureira P, Carvalho LS, Araújo A, O'Brien M, Popat S.

Pharmacogenomics. 2013 Nov;14(14):1765-77. doi: 10.2217/pgs.13.177. Review.


From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.

Mazzoni F, Rotella V, Pratesi N, Boni L, Simi L, Orlando C, Comin CE, Maddau C, Di Costanzo F.

Tumori. 2011 Mar-Apr;97(2):160-5. doi: 10.1700/667.7777.


Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.

Sun L, Zhang Q, Luan H, Zhan Z, Wang C, Sun B.

J Exp Clin Cancer Res. 2011 Mar 17;30:30. doi: 10.1186/1756-9966-30-30.


Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.

Malapelle U, Bellevicine C, Zeppa P, Palombini L, Troncone G.

Diagn Cytopathol. 2011 Sep;39(9):703-10. doi: 10.1002/dc.21512. Epub 2010 Nov 9. Review.


[Non-small cell lung cancer. Subtyping and predictive molecular marker investigations in cytology].

Savic S, Bihl MP, Bubendorf L.

Pathologe. 2012 Jul;33(4):301-7. doi: 10.1007/s00292-012-1577-9. Review. German.


Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.

van Eijk R, Licht J, Schrumpf M, Talebian Yazdi M, Ruano D, Forte GI, Nederlof PM, Veselic M, Rabe KF, Annema JT, Smit V, Morreau H, van Wezel T.

PLoS One. 2011 Mar 8;6(3):e17791. doi: 10.1371/journal.pone.0017791.


Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.

Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC.

Cancer. 2012 Feb 1;118(3):729-39. doi: 10.1002/cncr.26311. Epub 2011 Jun 30.


The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).

Gottschling S, Herpel E, Eberhardt WE, Heigener DF, Fischer JR, Köhne CH, Kortsik C, Kuhnt T, Muley T, Meister M, Bischoff HG, Klein P, Moldenhauer I, Schnabel PA, Thomas M, Penzel R.

Lung Cancer. 2012 Jul;77(1):183-91. doi: 10.1016/j.lungcan.2012.03.003. Epub 2012 Apr 7.

Items per page

Supplemental Content

Write to the Help Desk